account- Shares of BioMimetic Therapeutics Inc. lost a third of their value on Tuesday over concerns that a Food and Drug Administration panel will vote against approving the company's Augment bone graft.Augment is a synthetic material that is intended to...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to BioMimetic Therapeutics plunges on FDA concerns
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account